Antibody Secreting Cell and Cyotokine Profiles in Neonates on ECMO
Completed
Conditions studied: Persistent Fetal Circulation Syndrome, Diaphragmatic Hernia, Meconium Aspiration, Sepsis
In brief
Infants are placed on ECMO for correction of reversible respiratory failure. Often, because a few of the reasons for respiratory failure show us similar things in the baby, it is difficult to determine exactly which is causing the biggest problem. We are now capable of measuring certain cells and proteins in these infants that may help us more accurately diagnose the exact problem. We hypothesize that infants placed on ECMO will show unique antibody-secreting cells responses and patterns of cytokine and chemokine (protein) response to illness and to the ECMO circuit. If we find unique patterns to these cells or proteins, they may be able to predict outcomes or guide treatment of these infants.
Key facts
- Study ID
- NCT00371241
- Run by
- The University of Texas Health Science Center, Houston
- People needed
- 12
- Starts
- 2006-09-01
- Expected to finish
- 2007-11-01
- Last updated by the study team
- 2020-11-05
Who can join
Age: 0 and older, up to 0. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 1) term newborn infants >24 hours and ≤ 30 days old 2) Placed on ECMO in the NICU at MHCH 3) Parental consent obtained within 48 hours of being placed on ECMO
You may not qualify if…
- 1) Infant > 30 days old 2) Infant NOT on ECMO 3) Withdrawal of parental consent
Where it is running
- Memorial Hermann Hospital — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.